Wang et al. (2008) demonstrated that SDF-1/CXCR7 promoted Akt phosphorylation in prostate cancer. CXCR7 could also increase the p-Akt level in osteosarcoma (Zhang et al., 2014), bladder cancer (Hao et al., 2012), thyroid cancer (Zhu et al., 2016), and multiple myeloma (Azab et al., 2014). This evidence concerns the gene CXCL12 and AL amyloidosis.